Comparative Docking Study of Anibamine as the First Natural Product CCR5 Antagonist in CCR5 Homology Models
- 5 January 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 49 (1) , 120-132
Abstract
Anibamine, a novel pyridine quaternary alkaloid recently isolated from Aniba sp., has been found to effectively bind to the chemokine receptor CCR5 with an IC(50) at 1 microM in competition with (125)I-gp120, an HIV viral envelope protein binding to CCR5 with high affinity. Since CCR5, a G-protein-coupled receptor, is an essential coreceptor for the human immunodeficiency virus type I (HIV-1) entry to host cells, a CCR5 antagonist that inhibits the cellular entry of HIV-1 provides a new therapy choice for the treatment of HIV. Anibamine provides a novel structural skeleton that is remarkably different from all lead compounds previously identified as CCR5 antagonists. Here, we report comparative docking studies of anibamine with several other known CCR5 antagonists in two CCR5 homology models built based on the crystal structures of bovine rhodopsin and human beta(2)-adrenergic receptor. The binding pocket of anibamine has some common features shared with other high affinity CCR5 antagonists, suggesting that they may bind in similar binding sites and/or modes. At the same time, several unique binding features of anibamine were identified, and it will likely prove beneficial in future molecular design of novel CCR5 antagonists based on the anibamine scaffold.Keywords
This publication has 127 references indexed in Scilit:
- Unified QSAR approach to antimicrobials. Part 3: First multi-tasking QSAR model for Input-Coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compoundsBioorganic & Medicinal Chemistry, 2008
- Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligandsJournal of Computer-Aided Molecular Design, 2008
- On the Applicability of GPCR Homology Models to Computer-Aided Drug Discovery: A Comparison between In Silico and Crystal Structures of the β2-Adrenergic ReceptorJournal of Medicinal Chemistry, 2008
- Neoceptors: reengineering GPCRs to recognize tailored ligandsTrends in Pharmacological Sciences, 2007
- Crystal structure of a photoactivated deprotonated intermediate of rhodopsinProceedings of the National Academy of Sciences, 2006
- Hum-PLoc: A novel ensemble classifier for predicting human protein subcellular localizationBiochemical and Biophysical Research Communications, 2006
- Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial ChemistryJournal of Chemical Information and Computer Sciences, 2002
- Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. CohenJournal of Molecular Biology, 1997
- Molecular recognition of receptor sites using a genetic algorithm with a description of desolvationJournal of Molecular Biology, 1995
- Energy-optimized structure of antifreeze protein and its binding mechanismJournal of Molecular Biology, 1992